



# NewTherapiesSubgroup

## New Therapies Current Work Plan 2016

Drug	Date to be discussed	Details
<b>Safinamide</b>	July 2016	Parkinson's disease (early) <b>Now had EMA positive opinion and due to be launched soon.</b>
<b>Eluxadoline (oral)</b>		for irritable bowel syndrome (IBS), diarrhoea predominant  First-in-class compound that functions as a mu-opioid receptor agonist and delta-opioid receptor antagonist. <b>Due to be launched in 2016.</b>
<b>Colchicine for pericarditis pain</b>	July 2016	Unlicensed use
<b>Pregabalin/gabapentin for chronic cough</b>	July 2016	Unlicensed use
<b>Birch bark extract</b>	July 2016	
<b>DUAVIVE®</b>		New combination. conjugated oestrogens + SERM. Launched.
<b>Mepolizumab</b>		COPD.
<b>Ixekizumab</b>		Psoriasis
<b>Opicapone</b>		Parkinson's disease and motor fluctuation. Positive opinion received.
<b>Sirolimus eye drops</b>		Negative opinion from EMA so not licensed.

**Last updated July 2016**